Pharmablock Sciences announces early redemption of convertible bonds

Nanjing Pharmablock Sciences Co., Ltd. announced the early redemption of its "Yaoshi convertible bonds" (123145) at CNY 100.62 per bond, which includes the face value plus accrued interest. This decision follows the stock price meeting redemption conditions, closing at or above 130% of the current conversion price (CNY 43.69 per share) for at least 15 trading days between July 25, 2025, and August 14, 2025.

Key dates for bondholders are fast approaching: trading of the convertible bonds will cease on September 15, 2025, and the last day for conversion into shares is September 17, 2025. Any bonds not converted by the close of business on September 17, 2025, will be compulsorily redeemed at the stated price. The company strongly advises bondholders to consider converting their bonds into shares before the deadline, given the significant difference between the current market price of the convertible bonds and the redemption price.

The company also cautions that investors must have activated their GEM trading permissions to convert bonds into shares. Those who do not meet GEM stock suitability management requirements will be unable to convert their "Yaoshi convertible bonds" into shares, potentially facing losses. Redemption funds are expected to reach the China Securities Depository and Clearing Corporation account by September 23, 2025, and be credited to investors' accounts by September 25, 2025.